News Archive

Did you miss the first I-270 Bio Corridor event last month? If so, you missed out on learning about and connecting with some of the top bio and life science companies and experts as well as resource partners like REDI, the MD Department of Commerce, the Montgomery County Economic Development Corp, Frederick County Office of Economic Development, Frederick City, the City of Gaithersburg Office of Economic Development and Montgomery College.

Over 100 attendees enjoyed a happy hour and discussion of how best to help the I-270 corridor grow with more bio and life science companies at CRB’s new headquarters in Rockville.

This event was scheduled as a precursor to the BIO International Convention taking place this month in San Francisco, REDI, our I-270 Corridor partners, will be there in the Maryland pavilion with information and resources for those companies that may be looking for the perfect location for their bio and life science businesses, promoting the I-270 corridor a hub for this niche market.

When the federal government agreed to a major price hike for Nuo Therapeutics Inc.’s lead wound therapy product last October, officials at the Gaithersburg biotech felt it was the game changer they’d been waiting for.

Twenty-two finalists have been selected for the Maryland Incubator Company of the Year Awards.

bwtech@UMBC leads the incubator list with eight tenant companies up for awards. Previous winners include Emerging Technology Centers-based SocialToaster, Spark’s Avhana Health and Maryland Center for Entrepreneurship’s Milestone Sports.

The Centers for Medicare and Medicaid Services (CMS) and the Health and Human Services IDEA Lab are looking for a “talented, awesomely connected” entrepreneur-in-residence to shepherd creation of a new pre-certification process for IT vendors interested in working with states.

Few industries are facing as much external change as pharmaceuticals and medical products, whether it be sustained global demand and the need for drugs and devices, accelerating cost pressures on health systems, growing complexity in emerging markets, or the disruptive effect of new technologies in therapy and care provision.

The U.S. health care system has a tremendous need for novel high- (and low-) tech solutions to increase its quality, agility and affordability.

To meet this need, the National Science Foundation (NSF) supports research and early-stage development of novel biomedical products, processes and services.

Thursday, June 2, 2016 7:30 AM – 9:00 AM, Bethesda Country Club

An IPO is one of the most important events in a company’s history, and navigating the course requires an enormous amount of endurance. Choosing an investment bank, perfecting your roadshow, and meeting with investors is just the tip of the iceberg. Join Vit Vasista, Chief Financial Officer of REGENXBIO, at All the Right Moves: Planning a Successful Exit Strategy, on Thursday, June 2, from 7:30 – 9:00 a.m. Vit will share tips that were integral to REGENXBIO’s successful 2015 IPO, from pitching to trading.

On May 23, U.S. Senator Ben Cardin (D-Maryland) convened at Johns Hopkins Hospital a scientific expert panel to discuss what to do about the Zika epidemic. Organizing the event within two business days was no small feat, as Cardin, scientific experts, health department leaders, hospital executives and industry representatives all had to quickly clear their very busy morning schedules. The attendance of television and newspaper outlets (such as the Baltimore Sun) meant that the discussion’s proceedings would be available to the public. From the very start, Cardin kept the tone very science-focused: The Zika epidemic is a public health emergency, and the issue is how best scientifically, collaboratively and expeditiously to handle this emergency.

Life science venture firm 5AM Ventures has raised $285 million for fund number 5, according to data from a Form D filing with the U.S. Securities and Exchange Commission. The firm makes investments in life science startups at the seed and early stage of their development.

Two sets of numbers shows how far biopharma activity has progressed in Asia recently. The value of biotech venture capital funding during the first quarter zoomed to $174 million in the first quarter from $150 million in Q4 2015 and a mere $9.4 million in Q1 2015, according to Tech In Asia.